FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Dapsone

Drug and asset intelligence for Dapsone with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Macleods Pharmaceuticals →

Recent signals(2)

RegulatoryJuly 15, 2026

FDA Grants Approval for Dapsone ANDA218335 by Macleods Pharmaceuticals

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 218335 for Dapsone submitted by Macleods Pharmaceuticals.

StrategyJuly 1, 2026

FDA Approves Dapsone ANDA213414 by Alembic

The FDA has approved ANDA213414 for Dapsone submitted by Alembic.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

Macleods Pharmaceuticals — Dapsone

July 15, 2026 · N/A

Topline Data

Alembic Pharmaceuticals — Dapsone

July 1, 2026 · N/A

Indications

Infectious Disease →

Therapeutic areas

Antimicrobial →

Infectious Disease →

Infectious Disease · Antimicrobial →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.